Clene (CLNN) Stock Price, News & Analysis

Company Overview

Clene Inc. (NASDAQ: CLNN) is a clinical-stage biotechnology company focused on developing novel nanomedicines to treat neurodegenerative and neuroinflammatory disorders. The company’s core technology platform centers on a proprietary gold nanocrystal therapeutic, known as CNM-Au8, which is designed to enhance cellular energy production and provide antioxidant protection. Clene’s primary development programs target conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease, with multiple clinical trials underway to evaluate safety and efficacy in these patient populations.

CNM-Au8 leverages catalytic nanotechnology to support cellular bioenergetics and reduce oxidative stress, mechanisms implicated in the progression of neurodegeneration. In addition to its lead program for ALS, Clene is advancing clinical studies in relapsing-remitting MS and Parkinson’s disease, and is exploring broader applications of its platform in other neurological indications. The company’s research and manufacturing operations are supported by partnerships with academic institutions and specialized contract development and manufacturing organizations (CDMOs).

Founded in 2014 and headquartered in Salt Lake City, Utah, Clene maintains research collaborations and regulatory engagement across North America, Europe and Australia. The company went public on the Nasdaq in 2020, positioning itself to expand clinical development and scale the manufacturing of its nanocatalyst technology. Clene’s regulatory strategy has included obtaining orphan drug designations and fast-track status from the U.S. Food and Drug Administration to expedite development in rare neurodegenerative disorders.

Clene’s leadership team comprises experienced professionals in biotechnology research, clinical development, regulatory affairs and finance. Guided by a board of directors with deep expertise in neuroscience and pharmaceuticals, the company continues to advance its pipeline through collaborative research efforts, strategic partnerships and ongoing engagement with patient advocacy groups. Clene aims to transform the treatment paradigm for debilitating neurological diseases by harnessing the potential of nanomedicine.

Key Stats

• Today's Range: $3.71 to $3.98
• 50-Day Range: $2.37 to $4.90
• 52-Week Range: $2.28 to $6.96
• Volume: 32,963 shs
• Average Volume: 89,071 shs
• Market Capitalization: $31.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.00
• Consensus Rating: Buy

Clene Stock Analysis - MarketRank™

Clene scored higher than 69% of companies evaluated by MarketBeat, and ranked 325th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Clene has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Clene has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Clene are expected to grow in the coming year, from ($5.19) to ($4.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clene is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clene is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.51% of the float of Clene has been sold short.

Short Interest Ratio / Days to Cover

Clene has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clene has recently decreased by 24.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clene does not currently pay a dividend.

Dividend Growth

Clene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.51% of the float of Clene has been sold short.

Short Interest Ratio / Days to Cover

Clene has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clene has recently decreased by 24.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Clene has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Clene this week, compared to 1 article on an average week.

Search Interest

5 people have searched for CLNN on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,029.00 in company stock.

Percentage Held by Insiders

35.30% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 23.28% of the stock of Clene is held by institutions.

CLNN Stock Analysis - Frequently Asked Questions

How have CLNN shares performed this year?

Clene's stock was trading at $5.31 at the beginning of 2025. Since then, CLNN shares have decreased by 28.1% and is now trading at $3.82.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) posted its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.60. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.07 million.

When did Clene's stock split?

Clene shares reverse split on Thursday, July 11th 2024.The 1-20 reverse split was announced on Thursday, July 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Clene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clene investors own include Waste Connections (WCN), AU Optronics (AUOTY), Voyager Therapeutics (VYGR), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLNN
• CIK: 1822791
• Web: clene.com
• Phone: 801-676-9695
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Clene: $40.00
• High Price Target: $83.00
• Low Price Target: $23.00
• Potential Upside/Downside: +923.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.40 million
• Net Margins: -8,306.00%
• Pretax Margin: -8,306.00%
• Return on Equity: N/A
• Return on Assets: -105.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.36
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $340 thousand
• Price / Sales: 95.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.06) per share
• Price / Book: -3.69

Miscellaneous

• Outstanding Shares: 8,270,000
• Free Float: 5,349,000
• Market Cap: $32.34 million
• Optionable: Optionable
• Beta: 0.55